Catium Convicap - Inhalation Capsule Indacaterol + Glycopyrronium - 27.5+15.6mcg 6 Inhalation Capsule(s) / Strip Incepta Pharmaceuticals Ltd. Introduction: Catium Convicap is used for the treatment of chronic obstructive pulmonary disorder (a lung disorder in which the flow of air to the lungs is blocked). It helps in relaxing the muscles of the air passages and making it easier to breathe. It relieves coughing, wheezing and feeling short of breath. Your doctor will tell you how often you need to use your inhaler. The effect of this medicine may be noticeable after a few days but will only reach its maximum after a few weeks. This medicine must be used regularly to be effective, so go on taking it... Uses of Catium Convicap: Chronic obstructive pulmonary disease (COPD) Side effects of Catium Convicap: IndigestionHigh blood pressureNasopharyngitis (inflammation of the throat and nasal passages)Chest painFeverUrinary retentionSore throatCoughHeadacheDizzinessAllergic reactionIncreased glucose level in bloodInflammation of the noseSinus inflammationUrinary tract infection How to use Catium Convicap: Take this medicine in the dose and duration as advised by your doctor. Check the label before use. How Catium Convicap works: Catium Convicap is a combination of two medicines: Indacaterol and Glycopyrrolate which treat chronic obstructive pulmonary disease (COPD). Indacaterol is a bronchodilator which works by relaxing the muscles in the airways and widens the airways. Glycopyrrolate is an anticholinergic which works by decreasing the secretions in the airways. Together, they make breathing easier. Indication: Bronchodilator treatment to relieve symptoms in patients with, chronic obstructive pulmonary disease (COPD). Administration: For inhalation use only. The capsules must not be swallowed. Adult Dose: Adult Chronic Obstructive Pulmonary Disease (COPD) Inhale 1 cap with inhaler once daily. Hepatic Impairment: This can be used at the recommended dose in patients with mild and moderate hepatic impairment. There are no data available for the use of Indacaterol + Glycopyrronium Breezhaler in patients with severe hepatic impairment, therefore caution should be observed in these patients. Child Dose: Safety and efficacy not established Renal Dose: Renal Impairment: This can be used at the recommended dose in patients with mild to moderate renal impairment. In patients with severe renal impairment or end-stage renal disease requiring dialysis it should be used only if the expected benefit outweighs the potential risk. Contraindication: Hypersensitivity to indacaterol, glycopyrronium or to any of the excipients of Indacaterol + Glycopyrronium. All LABAs are contraindicated in patients with asthma without use of a long-term asthma control medication Indacaterol/glycopyrrolate is not indicated for the treatment of asthma Use in children: This should not be used in patients <18 years. Mode of Action: Glycopyrronium: Long-acting muscarinic antagonist (LAMA); often referred to as an anticholinergic; produces bronchodilation by inhibiting acetylcholine’s effect on muscarinic receptors in the airway smooth muscle Indacaterol: Long-acting beta2-agonist (LABA); stimulates intracellular adenyl cyclase, causing conversion of ATP to cyclic AMP; increased cyclic AMP levels cause relaxation of bronchial smooth muscle Precaution: Concomitant use w/ long-acting beta-agonists or long-acting muscarinic antagonists. Not for the treatment of asthma. Immediately discontinue use if hypersensitivity & paradoxical bronchospasm occurs. Narrow-angle glaucoma, urinary retention, CV disorders (CAD, acute MI, cardiac arrhythmia, HTN), convulsive disorders or thyrotoxicosis, severe renal impairment; hypokalaemia; hyperglycaemia. Pregnancy & lactation. Side Effect: 1-10% Nasopharyngitis (4.1%),Hypertension (2%),Back pain (1.8%),Oropharyngeal pain (1.6%) Interaction: Decreases levodopa effects. Effects may be enhanced by using drugs with antimuscarinic properties or MAOIs concurrently. May antagonise the GI effects of cisapride, metoclopramide and dompeidone. Potentially Fatal: IV admin in the presence of cyclopropane anesth can result in ventricular arrhythmias.